Code Product Name Standardization Functional Activity
0301 Calebin A (1) New
CurCousin
GRAS AFFIRMED
99% Calebin A Joint support
Liver health support
Metabolic health support
Weight management support
0336 Chrysin 97% Dihydroxyflavone Anti-inflammatory support
Cognitive health support
Sports nutrition
0522 Diindolylmethane (DIM) 98% DIM Antioxidant support
Bone health
0472 Forskolin Carbonate 98% Forskolin Carbonate Weight management support
0912 Indole-3-Carbinol 99.6% Indole-3-Carbinol Antioxidant support
Joint support
2100 Ipriflavone 98.5% Ipriflavone Bone health
1458 Oxyresveratrol (2)
OxyResvenox®
95% Oxyresveratrol Antioxidant support
Immune support
Support heart health
1819 Resveratrol (2)
Resvenox®
99% Resveratrol Antioxidant support
Immune support
Support heart health
2022 Tetrahydrocurcuminoids ODS
Curcumin C3 Reduct® ODS
95% Tetrahydrocurcuminoids Anti-inflammatory support
Antioxidant support
Oral health

PATENTS

(1) Calebin A (CurCousin)

 US 8,933,121; US 9,328,330; AU2012366253; AU2014203122; CA2857543; JP6374716; KR10-1702702; NZ614076; NZ 715053; RU2543334; SG192695; ZA2013/05918; ZL201280012577.3: Anti-obesity potential of calebin A. US 9,610,273; US 9,668,999; AU2014202312; CA2850999; CA2963383; EA027148; EP2937084; HK1210590; I-622384; JP6263707; KR10-1647549; NZ624269; MY-170067-A; PH1-2014-000244: Method for the treatment of hypercholesterolemia

 IDP000064827: Calebin A and its effect on hypercholesterolemia

 US 9,220,703; AU2014201769; CA2935898;EP2893926; JP6142446; KR10-1685263; KR10-1685333; MY-175867-A; NZ622909; PH1-2016-501138; SG11201605336Y: Composition and method for the protection of articular cartilage

 EA027614: Use of calebin A to protect mammalian articular cartilage from pathological damage

 US 9,365,486; AU2014203764; CA2858126; EA027726; EP2963007; HK1217689; JP6490927; KR10-1629561; NZ627247: Synthesis of calebin A and its biologically active analogs

 HK1210028: Calebin A for articular cartilage

 EP3085370: Calebin A for inducing lipolysis

 US 9,737,502; CA2893321; IDP000067993; JP6336943; KR10-1763474; MY-182000-A; PH1-2015-000188; RU2643297; SG10201503805X: Calebin A for hepatic steatosis

 US 9,539,232; CA2941050; RU2653103: Calebin A for osteoporosis

 EP2663185; HK1190874: Calebin A for use in the treatment of inflammation and obesity

 EP3085370: Calebin A for inducing lipolysis

(2) Oxyresvenox® / Resvenox®

 US 7,253,324: Process for the synthesis of biologically active oxygenated compounds by dealkylation of the corresponding alkylethers


Disclaimer

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.